WeVote
Log In

Bill

Bill

HB 1377

Prescription Drug Repository Program - Redirecting Safe Prescription Drugs Pilot Program

2026 Regular Session Introduced by Tiffany Alston and 20 co-sponsors

Maryland establishes a pilot program to collect unused prescription drugs and redistribute them to uninsured/underinsured residents, balancing medication access with waste reduction.

Approved by the Governor - Chapter 243
0
WeVote Research Nonpartisan
Bill Summary · HB 1377

Legislative bill overview

HB 1377 establishes a prescription drug repository program in Maryland that collects unused, safe prescription medications from residents and redistributes them to uninsured or underinsured individuals who cannot afford their medications. This pilot program aims to reduce medication waste while increasing access to affordable pharmaceuticals for vulnerable populations.

Why is this important

High prescription drug costs create barriers to medication access for many Marylanders, potentially leading to untreated conditions and worse health outcomes. By creating a legal framework to safely redistribute unused medications, the state could simultaneously address medication waste (an environmental and economic concern) and expand affordable drug access without creating new government expenditures.

Potential points of contention

  • Safety and liability concerns: Redistributing used medications raises questions about proper storage conditions, expiration dating, contamination risks, and who bears liability if redistributed drugs cause harm
  • FDA and federal law compliance: Federal regulations generally prohibit redistribution of prescription medications; the bill must clearly navigate whether it conflicts with federal pharmacy law or requires federal waivers
  • Pharmaceutical industry opposition: Drug manufacturers may oppose the program as it reduces medication sales, potentially leading to legal challenges or lobbying against implementation
  • Program administration costs and oversight: Establishing infrastructure for collection, verification, storage, and redistribution requires funding and regulatory oversight that may be underestimated
  • Equity in access: Without clear distribution criteria, the program could inadvertently create disparities in who receives redistributed medications

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.